Skip to content

US · NBTX · BIOTECHNOLOGY

Nanobiotix S.A. (NBTX) intrinsic value and stock valuation

$26.50as of 2026-11-21 · Mkt cap 2.01B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Nanobiotix S.A. DCF and intrinsic value

InvestorsCraft values NBTX with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from NBTX’s statements →

Nanobiotix S.A. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Paris, IF 75012 nanobiotix.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$29.6M+66.3% 5y CAGRd
20112025
Net income
-$-23.96M
20112025
Free cash flow
-$-33.97M
20112025
Total equity
-$-84.48M
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$29.6M-$-7.19M$36.2M$4.78M$2.65M
Operating income-$-10.82M-$-68.39M-$-26.78M-$-46.7M-$-52.58M
Net income-$-23.96M-$-68.13M-$-39.7M-$-57.04M-$-47M
EPSd-$-501.05K-$-1.44M-$-1.08M-$-1.64M-$-1.35M
Operating cash flow-$-33.42M-$-19.55M-$-12.48M-$-37.1M-$-29.87M
Capital expenditure-$-550K-$-850K-$-330K-$-90K-$-230K
Free cash flow-$-33.97M-$-20.4M-$-12.8M-$-37.2M-$-30.1M
Total assets$67.8M$67.4M$93.9M$59.8M$101.8M
Total debt$95.3M$50.9M$50.6M$53.2M$46M
Net debt$42.6M$1.17M-$-24.72M$11.8M-$-37.9M
Total equity-$-84.48M-$-65.7M-$-1.84M-$-27.05M$26.8M
Cash and short-term investments$52.8M$49.7M$75.3M$41.4M$84.2M
Income statement
20252024202320222021
Revenue$29.6M-$-7.19M$36.2M$4.78M$2.65M
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$29.6M-$-7.19M$36.2M$4.78M$2.65M
Research and development expenses$23.1M$40.5M$38.4M$32.6M$30.4M
Selling, general and administrative expenses$20.2M$20.5M$22.1M$17.9M$19.4M
Other expenses-$-2.88M$130K$2.54M$980K$5.41M
Operating expenses$40.5M$61.2M$63M$51.5M$55.2M
Cost and expenses$40.5M$61.2M$63M$51.5M$55.2M
Interest income$980K$2.63M$1.22M$260K$0.00
Interest expense$10.4M$8.09M$7.98M$5.84M$700K
Depreciation and amortization$1.5M$590K$550K$1.5M$1.56M
Ebitda-$-12.07M-$-67.67M-$-23.69M-$-44.22M-$-45.6M
Operating income-$-10.82M-$-68.39M-$-26.78M-$-46.7M-$-52.58M
Total other income/expenses, net-$-13.14M$360K-$-12.8M-$-10.33M$5.58M
Income before tax-$-23.96M-$-68.03M-$-39.58M-$-57.03M-$-47M
Income tax expense$0.00$100K$120K$10K$10K
Net income-$-23.96M-$-68.13M-$-39.7M-$-57.04M-$-47M
Weighted average shares outstanding$47.8M$47.3M$36.8M$34.9M$34.7M
Weighted average diluted shares outstanding$47.8M$47.3M$36.9M$34.9M$34.7M
Balance sheet
20252024202320222021
Cash and short-term investments$52.8M$49.7M$75.3M$41.4M$84.2M
Net receivables$7.68M$8.54M$2.97M$2.84M$3.89M
Inventory$0.00$0.00$200K$2.98M$0.00
Total current assets$62.8M$61.5M$87.3M$52.4M$93.1M
Property, plant and equipment, net$4.57M$5.54M$6.11M$7.12M$8.19M
Goodwill and intangible assets$10K$10K$10K$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$100K
Total non-current assets$5.01M$5.95M$6.56M$7.41M$8.71M
Total assets$67.8M$67.4M$93.9M$59.8M$101.8M
Accounts payable$6.58M$4.48M$6.7M$4M$5M
Short-term debt$4.31M$4.92M$5.02M$4.56M$8.2M
Deferred revenue$36.2M$18.2M$18.2M$16.6M$16.8M
Total current liabilities$57.5M$58.9M$49.9M$37.9M$36.8M
Long-term debt$91M$46M$45.5M$48.6M$37.8M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$94.7M$74.2M$45.9M$48.9M$38.1M
Capital lease obligations$3.1M$4.23M$5.08M$5.53M$6.52M
Total liabilities$152.2M$133.1M$95.7M$86.8M$75M
Common stock$1.45M$1.42M$1.41M$1.05M$1.04M
Retained earnings-$-23.96M-$-68.13M-$-39.7M-$-57.04M-$-47M
Accumulated other comprehensive income (loss)-$-376.14M-$-311.51M-$-276.07M-$-226.58M-$-182.82M
Total equity-$-84.48M-$-65.7M-$-1.84M-$-27.05M$26.8M
Total investments$0.00$0.00$0.00$0.00$100K
Total debt$95.3M$50.9M$50.6M$53.2M$46M
Net debt$42.6M$1.17M-$-24.72M$11.8M-$-37.9M
Cash flow statement
20252024202320222021
Net income-$-23.96M-$-68.13M-$-39.7M-$-57.04M-$-47M
Depreciation and amortization$1.5M$1.62M$1.51M$1.5M$1.56M
Stock-based compensation$3.54M$4.3M$3.3M$3.17M$3.2M
Change in working capital-$-3.4M$130K-$-370K-$-610K-$-4.7M
Accounts receivable$1.85M-$-2.07M-$-810K-$-100K$60K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-33.42M-$-19.55M-$-12.48M-$-37.1M-$-29.87M
Investments in property, plant and equipment-$-540K-$-850K-$-330K-$-90K-$-230K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-580K-$-950K-$-350K$140K-$-240K
Common stock issued$1.53M$0.00$0.00$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$37.4M-$-5.13M$46.8M-$-5.65M-$-5.18M
Net change in cash$3.01M-$-25.55M$33.9M-$-42.53M-$-35.23M
Cash at end of period$52.8M$49.7M$75.3M$41.4M$83.9M
Operating cash flow-$-33.42M-$-19.55M-$-12.48M-$-37.1M-$-29.87M
Capital expenditure-$-550K-$-850K-$-330K-$-90K-$-230K
Free cash flow-$-33.97M-$-20.4M-$-12.8M-$-37.2M-$-30.1M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Nanobiotix S.A.

        Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.

        CEO
        Laurent Levy
        Employees
        97
        Beta
        0.57

        Explore

        Frequently asked questions

        What is the intrinsic value of Nanobiotix S.A. (NBTX)?

        Nanobiotix S.A. (NBTX) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is NBTX undervalued?

        NBTX trades at a price of $26.50 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.